173 related articles for article (PubMed ID: 38887055)
1. Bridging the gap: The future of biosimilars regulations.
Jarab AS; Abu Heshmeh SR; Al Meslamani AZ
Hum Vaccin Immunother; 2024 Dec; 20(1):2362450. PubMed ID: 38887055
[TBL] [Abstract][Full Text] [Related]
2. Global regulatory standards for the approval of biosimilars.
Mounho B; Phillips A; Holcombe K; Grampp G; Lubiniecki T; Mollerup I; Jones C
Food Drug Law J; 2010; 65(4):819-37, ii-iii. PubMed ID: 24479248
[TBL] [Abstract][Full Text] [Related]
3. Regulatory and clinical considerations for biosimilar oncology drugs.
Bennett CL; Chen B; Hermanson T; Wyatt MD; Schulz RM; Georgantopoulos P; Kessler S; Raisch DW; Qureshi ZP; Lu ZK; Love BL; Noxon V; Bobolts L; Armitage M; Bian J; Ray P; Ablin RJ; Hrushesky WJ; Macdougall IC; Sartor O; Armitage JO
Lancet Oncol; 2014 Dec; 15(13):e594-e605. PubMed ID: 25456378
[TBL] [Abstract][Full Text] [Related]
4. Update on Biosimilars in Asia.
Tsai WC
Curr Rheumatol Rep; 2017 Aug; 19(8):47. PubMed ID: 28718062
[TBL] [Abstract][Full Text] [Related]
5. Current Japanese Regulatory Systems for Generics and Biosimilars.
Kuribayashi R; Sawanobori K
J Pharm Sci; 2018 Mar; 107(3):785-787. PubMed ID: 29113922
[TBL] [Abstract][Full Text] [Related]
6. Optimizing use and addressing challenges to uptake of biosimilars.
Leber MB
Am J Manag Care; 2018 Nov; 24(21 Suppl):S457-S461. PubMed ID: 30452214
[TBL] [Abstract][Full Text] [Related]
7. Demystifying biosimilars: development, regulation and clinical use.
Rugo HS; Rifkin RM; Declerck P; Bair AH; Morgan G
Future Oncol; 2019 Mar; 15(7):777-790. PubMed ID: 30500264
[TBL] [Abstract][Full Text] [Related]
8. Challenges Faced by the Biopharmaceutical Industry in the Development and Marketing Authorization of Biosimilar Medicines in BRICS-TM Countries: An Exploratory Study.
Rahalkar H; Sheppard A; Lopez-Morales CA; Lobo L; Salek S
Pharmaceut Med; 2021 Jul; 35(4):235-251. PubMed ID: 34292558
[TBL] [Abstract][Full Text] [Related]
9. Current market and regulatory landscape of biosimilars.
Bhatt V
Am J Manag Care; 2018 Nov; 24(21 Suppl):S451-S456. PubMed ID: 30452213
[TBL] [Abstract][Full Text] [Related]
10. Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions.
Bennett CL; Schoen MW; Hoque S; Witherspoon BJ; Aboulafia DM; Hwang CS; Ray P; Yarnold PR; Chen BK; Schooley B; Taylor MA; Wyatt MD; Hrushesky WJ; Yang YT
Lancet Oncol; 2020 Dec; 21(12):e575-e588. PubMed ID: 33271114
[TBL] [Abstract][Full Text] [Related]
11. Biosimilars in Developed and Developing East and Southeast Asian Countries: Japan, South Korea, and Malaysia-Overview, Evolution, and Regulations Assessment.
Bas TG; Oliu Castillo C
Biomed Res Int; 2016; 2016():5910403. PubMed ID: 27213153
[TBL] [Abstract][Full Text] [Related]
12. Comparability and biosimilarity: considerations for the healthcare provider.
Lee JF; Litten JB; Grampp G
Curr Med Res Opin; 2012 Jun; 28(6):1053-8. PubMed ID: 22519391
[TBL] [Abstract][Full Text] [Related]
13. Biosimilars in the United States: Emerging Issues in Litigation.
Wong AY; Rumore MM; Chan AW
BioDrugs; 2017 Jun; 31(3):189-205. PubMed ID: 28424972
[TBL] [Abstract][Full Text] [Related]
14. Biosimilars: A Value Proposition.
de Mora F
BioDrugs; 2019 Aug; 33(4):353-356. PubMed ID: 31175631
[TBL] [Abstract][Full Text] [Related]
15. Pharmacist perspectives and considerations for implementation of therapeutic oncology biosimilars in practice.
Cuellar S; McBride A; Medina P
Am J Health Syst Pharm; 2019 Oct; 76(21):1725-1738. PubMed ID: 31612935
[TBL] [Abstract][Full Text] [Related]
16. Biosimilars: Here and Now.
Lemery SJ; Esteva FJ; Weise M
Am Soc Clin Oncol Educ Book; 2016; 35():e151-7. PubMed ID: 27249717
[TBL] [Abstract][Full Text] [Related]
17. The rise of biosimilars: How they got here and where they are going.
Patel D; Gillis C; Naggar J; Mistry A; Mantzoros CS
Metabolism; 2017 Oct; 75():45-53. PubMed ID: 28939017
[TBL] [Abstract][Full Text] [Related]
18. Strategies for Overcoming Barriers to Adopting Biosimilars and Achieving Goals of the Biologics Price Competition and Innovation Act: A Survey of Managed Care and Specialty Pharmacy Professionals.
Greene L; Singh RM; Carden MJ; Pardo CO; Lichtenstein GR
J Manag Care Spec Pharm; 2019 Aug; 25(8):904-912. PubMed ID: 31007119
[TBL] [Abstract][Full Text] [Related]
19. Current Status of Biosimilars in Oncology.
Camacho LH
Drugs; 2017 Jun; 77(9):985-997. PubMed ID: 28477160
[TBL] [Abstract][Full Text] [Related]
20. The regulatory landscape of biosimilars: Algeria's efforts and progress made from 2006 to 2021.
Benahzil MA; Hadjaz IM; Mansouri K
Ann Pharm Fr; 2022 Jul; 80(4):440-447. PubMed ID: 34767827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]